Anthropic will start an internal drug discovery program, part of a new push to sell artificial intelligence tools to drugmakers.

On Tuesday, Anthropic announced Claude Science, a new product that company leaders describe as an AI workbench for scientific research.

The launch is part of Anthropic's life sciences and healthcare initiative, which the IPO-bound company has been developing since October 2025.